News

The product is currently marketed by Laboratoires Thea in Europe under the brand name of Virgan. Sirion licensed the rights to Virgan for the US from Laboratoires Thea

The research demonstrated that Onconase significantly inhibited tumor growth by inducing apoptosis (cell death) in human non-small cell lung cancer (NSCLC) cells and human breast cancer cells without

Results of the studies demonstrated a potent, dose-dependent inhibition of tumor growth following the administration of the compound ENMD-1420 in two distinct preclinical models of metastatic lung and

Telaprevir was evaluated in combination with pegylated interferon and ribavirin in treatment-naive, genotype 1-infected hepatitis C patients. In the study, 88% and 79% of patients receiving telaprevir achieved

The company received European Union marketing authorization for Thelin in August 2006. Thelin is the first selective endothelin A receptor antagonist and the first once-daily oral treatment available

ThromboGenics said it is outlicensing its stem cell research platform as part of a strategic plan to invest resources in its preclinical pipeline. Revenue derived from this license

GPC Biotech is requesting the approval of satraplatin as a treatment in combination with prednisone for patients with hormone-refractory prostate cancer whose prior chemotherapy has failed. Priority review

The new dose will treat specific patient populations, including those with renal and hepatic impairment. Risperdal Consta is manufactured by Alkermes and marketed in the US by Janssen.

These data showed that patients who experienced recurrent levels of hepatitis B virus in the blood after interruption of treatment with Baraclude also achieved liver enzyme (ALT) normalization.